WO2005116032A3 - Reverse-turn mimetics and method relating thereto - Google Patents

Reverse-turn mimetics and method relating thereto Download PDF

Info

Publication number
WO2005116032A3
WO2005116032A3 PCT/US2005/012799 US2005012799W WO2005116032A3 WO 2005116032 A3 WO2005116032 A3 WO 2005116032A3 US 2005012799 W US2005012799 W US 2005012799W WO 2005116032 A3 WO2005116032 A3 WO 2005116032A3
Authority
WO
WIPO (PCT)
Prior art keywords
reverse
disease
turn
biologically active
disclosed
Prior art date
Application number
PCT/US2005/012799
Other languages
French (fr)
Other versions
WO2005116032A2 (en
Inventor
Sung Hwan Moon
Jae Uk Chung
Sung Chan Lee
Masakatsu Eguchi
Michael Kahn
Kwang Won Jeong
Cu Nguyen
Soo Jin Lee
Original Assignee
Choongwae Pharma Corp
Sung Hwan Moon
Jae Uk Chung
Sung Chan Lee
Masakatsu Eguchi
Michael Kahn
Kwang Won Jeong
Cu Nguyen
Soo Jin Lee
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Choongwae Pharma Corp, Sung Hwan Moon, Jae Uk Chung, Sung Chan Lee, Masakatsu Eguchi, Michael Kahn, Kwang Won Jeong, Cu Nguyen, Soo Jin Lee filed Critical Choongwae Pharma Corp
Priority to NZ550691A priority Critical patent/NZ550691A/en
Priority to MXPA06011983A priority patent/MXPA06011983A/en
Priority to CN2005800110354A priority patent/CN1942472B/en
Priority to EP05778652A priority patent/EP1740588A2/en
Priority to BRPI0509888-2A priority patent/BRPI0509888B1/en
Priority to JP2007508556A priority patent/JP5021459B2/en
Priority to AU2005247859A priority patent/AU2005247859B2/en
Priority to CA2562693A priority patent/CA2562693C/en
Priority to KR1020067021473A priority patent/KR101257824B1/en
Publication of WO2005116032A2 publication Critical patent/WO2005116032A2/en
Publication of WO2005116032A3 publication Critical patent/WO2005116032A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Conformationally constrained compounds that mimic the secondary structure of reverse-turn regions of biologically active peptides and proteins are disclosed. Such reverse-turn mimetic structures have utility over a wide range of fields, including use as diagnostic and therapeutic agents. Libraries containing the reverse-turn mimetic structures of this invention are also disclosed as well as methods for screening the same to identify biologically active members. The invention also relates to the use of such compounds for inhibiting or treating disorders modulated by Wnt-signaling pathway, such as cancer, especially colorectal cancer, restenosis associated with angioplasty, polycystic kidney disease, aberrant angiogenesis disease, rheumatoid arthritis disease, tuberous sclerosis complex, Alzheimer's disease, excess hair growth or loss, or ulcerative colitis.
PCT/US2005/012799 2004-04-16 2005-04-15 Reverse-turn mimetics and method relating thereto WO2005116032A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
NZ550691A NZ550691A (en) 2004-04-16 2005-04-15 Reverse-turn mimetics and method relating thereto
MXPA06011983A MXPA06011983A (en) 2004-04-16 2005-04-15 Reverse-turn mimetics and method relating thereto.
CN2005800110354A CN1942472B (en) 2004-04-16 2005-04-15 Reverse-turn mimetics and method relating thereto
EP05778652A EP1740588A2 (en) 2004-04-16 2005-04-15 Reverse-turn mimetics and method relating thereto
BRPI0509888-2A BRPI0509888B1 (en) 2004-04-16 2005-04-15 REVERSE DIRECTION MIMETIC COMPOUNDS, PHARMACEUTICAL COMPOSITION AND THERAPEUTIC USES
JP2007508556A JP5021459B2 (en) 2004-04-16 2005-04-15 Reverse turn mimetics and related methods
AU2005247859A AU2005247859B2 (en) 2004-04-16 2005-04-15 Reverse-turn mimetics and method relating thereto
CA2562693A CA2562693C (en) 2004-04-16 2005-04-15 Reverse-turn mimetics and method relating thereto
KR1020067021473A KR101257824B1 (en) 2004-04-16 2005-04-15 Reverse-turn mimetics and method relating thereto

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/826,972 US7576084B2 (en) 2001-10-12 2004-04-16 Reverse-turn mimetics and method relating thereto
US10/826,972 2004-04-16

Publications (2)

Publication Number Publication Date
WO2005116032A2 WO2005116032A2 (en) 2005-12-08
WO2005116032A3 true WO2005116032A3 (en) 2006-04-13

Family

ID=35207478

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/012799 WO2005116032A2 (en) 2004-04-16 2005-04-15 Reverse-turn mimetics and method relating thereto

Country Status (11)

Country Link
US (4) US7576084B2 (en)
EP (1) EP1740588A2 (en)
JP (1) JP5021459B2 (en)
KR (1) KR101257824B1 (en)
CN (1) CN1942472B (en)
AU (1) AU2005247859B2 (en)
CA (1) CA2562693C (en)
MX (1) MXPA06011983A (en)
NZ (1) NZ550691A (en)
RU (1) RU2434017C2 (en)
WO (1) WO2005116032A2 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7671054B1 (en) 2001-10-12 2010-03-02 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US7576084B2 (en) * 2001-10-12 2009-08-18 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US8080657B2 (en) * 2001-10-12 2011-12-20 Choongwae Pharma Corporation Compounds of reverse turn mimetics and the use thereof
US7566711B2 (en) * 2001-10-12 2009-07-28 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US7232822B2 (en) 2001-10-12 2007-06-19 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
ES2570994T3 (en) * 2005-11-08 2016-05-23 Choongwae Pharma Corp Alpha-helix mimetics and method related to cancer stem cell treatment
MX2008011123A (en) 2006-03-28 2008-09-30 High Point Pharmaceuticals Llc Benzothiazoles having histamine h3 receptor activity.
JP2009538903A (en) * 2006-05-30 2009-11-12 チュンウェ ファーマ コーポレーション Composition for inducing or suppressing stem cell differentiation
SI2303887T1 (en) 2008-06-06 2015-12-31 Prism Pharma Co., Ltd. Alpha helix mimetics and methods relating thereto
EP2346871A1 (en) 2008-10-14 2011-07-27 PRISM BioLab Corporation Alpha helix mimetics in the treatment of cancer
SG175045A1 (en) * 2009-04-15 2011-11-28 Jw Pharmaceutical Corp Novel compounds of reverse-turn mimetics, method for manufacturing the same and use thereof
JP5768239B2 (en) 2009-05-07 2015-08-26 株式会社 ＰＲＩＳＭ ＢｉｏＬａｂ Alpha helix mimetics and related methods
EP2533048A4 (en) 2010-02-03 2013-08-21 Prism Biolab Co Ltd Compound capable of binding to naturally occurring denatured protein, and method for screening for the compound
KR102168006B1 (en) 2010-10-07 2020-10-20 유니버시티 오브 써던 캘리포니아 Cbp/catenin antagonists for enhancing asymmetric division of somatic stem cells
ES2552462T3 (en) 2010-10-14 2015-11-30 Jw Pharmaceutical Corporation New compound of a mimetic of reverse rotation and a procedure of production and use of the same
AU2011329854B2 (en) 2010-11-16 2017-03-30 University Of Southern California CBP/catenin antagonists for enhancing asymmetric division of somatic stem cells
US20140051706A1 (en) * 2011-02-25 2014-02-20 Prism Pharma Co., Ltd. Alpha helix mimetics and methods relating thereto
US9353119B2 (en) 2011-08-09 2016-05-31 Jw Pharmaceutical Corporation Composition for preventing and treating non-small cell lung cancer, containing pyrazino-triazine derivatives
WO2013022257A2 (en) * 2011-08-09 2013-02-14 제이더블유중외제약 주식회사 Composition for preventing and treating non-small cell lung cancer, containing pyrazino-triazine derivatives
EP2763995A4 (en) 2011-10-07 2015-05-27 Univ Southern California Cbp/catenin antagonists for enhancing asymmetric division of somatic stem cells
BR112014011737B1 (en) * 2011-11-16 2021-01-12 List Ag process for connecting functional elements to an axis
CN104205744B (en) * 2012-03-27 2017-03-01 索尼公司 Messaging device, information processing system and information processing method
EP2932977A4 (en) 2012-12-12 2016-08-10 Prism Pharma Co Ltd Prevention or treatment agent for hepatic fibrosis
CN107801379B (en) 2015-06-16 2021-05-25 卫材R&D管理有限公司 Anticancer agent
US10597398B2 (en) 2015-09-18 2020-03-24 National University Corporation Tottori University Suppression and regeneration promoting effect of low molecular weight compound on cancer and fibrosis
WO2017184808A1 (en) * 2016-04-20 2017-10-26 University Of Southern California Compounds and methods for increasing hematopoiesis
CN115023227A (en) 2019-10-29 2022-09-06 卫材R&D管理有限公司 Combination of a PD-1 antagonist, a VEGFR/FGFR/RET tyrosine kinase inhibitor and a CBP/beta-catenin inhibitor for the treatment of cancer
CN116925081A (en) * 2022-04-11 2023-10-24 中国科学院上海药物研究所 Cyclic peptide compound and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003031448A1 (en) * 2001-10-12 2003-04-17 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3120859A1 (en) 1981-05-26 1982-12-23 Basf Ag, 6700 Ludwigshafen DIHALOGEN ACETAMIDES, METHOD FOR THE PRODUCTION THEREOF AND HERBICIDAL AGENTS THAT CONTAIN ACETANILIDES AS AN HERBICIDE ACTIVE SUBSTANCES AND THESE DIHALOGEN ACETAMIDES AS AN ANTAGONISTIC AGENTS
US5475085A (en) * 1991-02-07 1995-12-12 Molecumetics, Ltd. Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same
CA2103577A1 (en) * 1991-02-07 1992-08-08 Michael Kahn Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same
JPH07509723A (en) 1992-08-06 1995-10-26 モレキュメティクス，リミティド Conformationally constrained mimetics of inverted turns and peptides containing the former
US5446128A (en) * 1993-06-18 1995-08-29 The Board Of Trustees Of The University Of Illinois Alpha-helix mimetics and methods relating thereto
US5693325A (en) * 1994-03-15 1997-12-02 Molecumetics, Ltd. Peptide vaccines and methods relating thereto
US6020331A (en) * 1995-03-24 2000-02-01 Molecumetics, Ltd. β-sheet mimetics and use thereof as protease inhibitors
US6245764B1 (en) * 1995-03-24 2001-06-12 Molecumetics Ltd. β-sheet mimetics and use thereof as inhibitors of biologically active peptides or proteins
US5840833A (en) * 1995-10-27 1998-11-24 Molecumetics, Ltd Alpha-helix mimetics and methods relating thereto
US6184223B1 (en) * 1995-10-27 2001-02-06 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
US5929237A (en) 1995-10-27 1999-07-27 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
US6013458A (en) * 1995-10-27 2000-01-11 Molecumetics, Ltd. Reverse-turn mimetics and methods relating thereto
ES2262184T3 (en) 1996-08-05 2006-11-16 Myriad Genetics, Inc. USE OF BETA SHEET MIMETICS AS PROTEASE AND KINASA INHIBITORS OR AS INHIBITORS OF TRANSCRIPTION FACTORS.
US6117896A (en) * 1997-02-10 2000-09-12 Molecumetics Ltd. Methods for regulating transcription factors
US6436989B1 (en) * 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
US6451972B1 (en) * 1998-11-16 2002-09-17 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Peptido-mimetic compounds containing RGD sequence useful as integrin inhibitors
IT1308787B1 (en) 1999-07-05 2002-01-10 Fiat Ricerche PROPULSION CONTROL SYSTEM FOR A VEHICLE.
US6294525B1 (en) 1999-09-01 2001-09-25 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
CA2284459C (en) 1999-10-04 2012-12-11 Neokimia Inc. Combinatorial synthesis of libraries of macrocyclic compounds useful in drug discovery
US6872825B2 (en) * 1999-12-21 2005-03-29 The Procter & Gamble Company Peptide β-turn mimetic compounds and processes for making them
DE10005631A1 (en) * 2000-02-09 2001-08-23 Max Planck Gesellschaft Arginine Mimetics as Factor X¶a¶ Inhibitors
GB2364210A (en) * 2000-06-30 2002-01-16 Nokia Oy Ab Diversity receiver and method of receiving a multi carrier signal
US6743937B2 (en) * 2000-07-17 2004-06-01 Oxigene, Inc. Efficient method of synthesizing combretastatin A-4 prodrugs
US7662960B2 (en) 2001-04-26 2010-02-16 Choongwae Pharma Corporation Beta-strand mimetics and method relating thereto
EP1406889A2 (en) 2001-07-09 2004-04-14 Pharmacia Italia S.p.A. Interaction inhibitors of tcf-4 with beta-catenin
US7232822B2 (en) * 2001-10-12 2007-06-19 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US20040072831A1 (en) 2001-10-12 2004-04-15 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US7566711B2 (en) * 2001-10-12 2009-07-28 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US7671054B1 (en) * 2001-10-12 2010-03-02 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US7576084B2 (en) * 2001-10-12 2009-08-18 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US6762185B1 (en) 2002-03-01 2004-07-13 Choongwae Pharma Corporation Compounds useful for treatment of cancer, compositions containing the same, and methods of their use
US6955985B2 (en) * 2002-06-28 2005-10-18 Kopin Corporation Domain epitaxy for thin film growth
PL377660A1 (en) 2003-02-13 2006-02-06 Sanofi-Aventis Deutschland Gmbh Nitrogen-substituted hexahydropyrazino[1,2-a]pyrimidine-4,7-dione derivatives, method for the production and use thereof as medicaments
CA2515735A1 (en) 2003-02-13 2004-08-26 Aventis Pharma Deutschland Gmbh Substituted hexahydropyrazino(1,2-a)pyrimidin-4,7-dion derivatives, method for the production and use thereof as medicaments
RU2383547C2 (en) 2003-08-28 2010-03-10 Чоонгвае Фарма Корпорейшн Modulation of beta-catenin/tcf-activated transcription
US7563825B1 (en) 2005-03-18 2009-07-21 Choongwae Pharma Corporation Modulation of beta-catenin coactivator interactions to effect stem cell growth or differentiation
ES2570994T3 (en) 2005-11-08 2016-05-23 Choongwae Pharma Corp Alpha-helix mimetics and method related to cancer stem cell treatment
KR20080073774A (en) 2005-11-28 2008-08-11 주식회사 중외제약 Serum-free expansion of cells in culture
SI2303887T1 (en) 2008-06-06 2015-12-31 Prism Pharma Co., Ltd. Alpha helix mimetics and methods relating thereto

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003031448A1 (en) * 2001-10-12 2003-04-17 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1740588A2 *

Also Published As

Publication number Publication date
US20150057283A1 (en) 2015-02-26
EP1740588A2 (en) 2007-01-10
CN1942472B (en) 2012-02-15
US8101751B2 (en) 2012-01-24
BRPI0509888A (en) 2007-10-16
CN1942472A (en) 2007-04-04
AU2005247859B2 (en) 2011-06-16
US7576084B2 (en) 2009-08-18
US20070021425A1 (en) 2007-01-25
RU2006140383A (en) 2008-05-27
CA2562693C (en) 2013-05-28
US20100081655A1 (en) 2010-04-01
RU2434017C2 (en) 2011-11-20
AU2005247859A1 (en) 2005-12-08
US8729262B2 (en) 2014-05-20
NZ550691A (en) 2010-10-29
JP2007532674A (en) 2007-11-15
KR101257824B1 (en) 2013-04-29
MXPA06011983A (en) 2007-08-14
CA2562693A1 (en) 2005-12-08
KR20070008637A (en) 2007-01-17
JP5021459B2 (en) 2012-09-05
WO2005116032A2 (en) 2005-12-08
US20110257185A1 (en) 2011-10-20

Similar Documents

Publication Publication Date Title
WO2005116032A3 (en) Reverse-turn mimetics and method relating thereto
WO2004093828A3 (en) Reverse-turn mimetics and method relating thereto
ATE398129T1 (en) REVERSE-TURN MIMETICS AND RELATED METHOD
ATE203025T1 (en) REVERSE TURN MIMETICS AND RELATED METHOD
WO2009051397A3 (en) Novel compounds of reverse turn mimetics and the use thereof (3)
WO2002050066A3 (en) Pyrazole compounds useful as protein kinase inhibitors
EA200001188A1 (en) PIRROLO [2,3-d] PYRIMIDINE COMPOUNDS
WO2001016135A3 (en) Reverse-turn mimetics and methods relating thereto
WO2003029209A3 (en) Chemical compounds
CY1111542T1 (en) RSV SUPPLIERS
WO2006094187A3 (en) Phthalazine, aza- and diaza-phthalazine compounds and methods of use
WO2006002177A3 (en) Interferon alpha receptor 1 antibodies and their uses
WO2006050389A3 (en) Pyridazine compounds, compositions and methods
WO2007008712A3 (en) Anti-alpha v beta 6 antibodies and uses thereof
WO2006004924A3 (en) Imidazolo-related compounds, compositions and methods for their use
WO2004094473A3 (en) Humanized antibodies to interferon alpha receptor-1 (ifnar-1)
WO2005038009A3 (en) Production of tacrolimus (fk-506) using new streptomyces species
WO2006050359A3 (en) Pyridazine compounds and methods
WO2002092010A3 (en) Reverse-turn mimetics and methods relating thereto
WO2003015780A8 (en) Isoxazolopyridinones and use thereof in the treatment of parkinson's disease
DE60226253D1 (en) HUMANIZED ANTIBODY AGAINST FIBROBLAST GROWTH FACTOR 8 AND ANTIBODY FRAGMENT
BRPI0318325B8 (en) beta-tape mimetic compounds
WO2004000313A3 (en) Treatment of amyotrophic lateral sclerosis using pgc-1 activity-modulating compounds
WO2004037179A3 (en) Substituted peptides useful in the treatment of alzheimer’s disease
WO2003038114A3 (en) Methods and compositions for the diagnosis and treatment of cellular proliferation disorders using 86604

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005247859

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200580011035.4

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2562693

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1020067021473

Country of ref document: KR

Ref document number: PA/a/2006/011983

Country of ref document: MX

Ref document number: 2007508556

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 550691

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2005247859

Country of ref document: AU

Date of ref document: 20050415

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005247859

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2005778652

Country of ref document: EP

Ref document number: 6619/DELNP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2006140383

Country of ref document: RU

WWP Wipo information: published in national office

Ref document number: 2005778652

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020067021473

Country of ref document: KR

ENP Entry into the national phase

Ref document number: PI0509888

Country of ref document: BR